Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Next Previous
X
Search
Trial Profile

A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fasinumab (Primary) ; Naproxen
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FACT OA1
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 10 Sep 2021 Status changed from active, no longer recruiting to completed.
    • 08 Sep 2020 Planned End Date changed from 8 Mar 2022 to 20 Aug 2021.
    • 05 Aug 2020 According to a Teva Pharmaceutical Industries media release, fasinumab 1 mg every two months showed numerical benefit over placebo, but did not reach statistical significance.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top